-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

2836 Measurable Residual Disease Monitoring for Philadelphia Positive Acute Lymphoblastic Leukemia (Ph+ALL) in the Setting of the Gimema ALL2820 Trial

Program: Oral and Poster Abstracts
Session: 614. Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers, and Minimal Residual Disease in Diagnosis and Prognosis: Poster II
Hematology Disease Topics & Pathways:
Research, ALL, Lymphoid Leukemias, Translational Research, Diseases, Lymphoid Malignancies, Technology and Procedures, Measurable Residual Disease , Molecular testing
Sunday, December 8, 2024, 6:00 PM-8:00 PM

Marco Beldinanzi1*, Vittorio Bellomarino1*, Deborah Cardinali, PhD1*, Irene Della Starza, PhD2*, Mabel Matarazzo1*, Mariangela Di Trani1*, Matteo Leoncin3*, Clara Minotti1*, Lara Pochintesta4*, Erika Borlenghi, MD5, Caterina Alati, MD6*, Simona Sica, MD, PhD7*, Valentina Mancini, MD8*, Barbara Scappini9*, Bianca Serio, MD10*, Marina Parisi11*, Lucia Ammirati, MD12*, Antonella Cucca13*, Federico Lussana14*, Ernesta Audisio, MD15*, Federico Mosna16*, Patrizia Zappasodi17*, Monica Bocchia, MD18*, Silvia Imbergamo19*, Mario Luppi, MD20*, Valeria Cardinali, MD, PhD21*, Crescenza Pasciolla22*, Claudio Romani23*, Albana Lico24*, Benedetta Cambò, MD25*, Massimiliano Bonifacio, MD26*, Monica Messina, PhD27*, Daniele G. Mattei, MD28, Sara Mastaglio, MD29*, Lara Aprile, PhD, MD30*, Monia Lunghi31*, Anna Guarini, PhD1*, Robin Foà, MD1* and Sabina Chiaretti, MD, PhD1

1Department of Translational and Precision Medicine, Division of Hematology, Sapienza University, Rome, Italy
2AIL Roma ODV, Rome, Italy
3Azienda Ulss3 Serenissima,Hematology Unit, Ospedale dell'Angelo, Venezia, Italy
4ASL DI PIACENZA, OSPEDALE "GUGLIELMO DA SALICETO", Piacenza, Italy
5Hematology, ASST Spedali Civili di Brescia, Brescia, Italy
6U.O.C. Ematologia, Grande Ospedale Metropolitano Bianchi Melacrino Morelli, Reggio Calabria, Italy
7UOC Ematologia e Trapianto Cellule Staminali Emopoietiche, Fondazione Policlinico Universitario A. Gemelli IRCCS Roma, Rome, Italy
8Department of Hematology and Oncology, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy
9Hematology Unit, Hematology Unit, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy
10Hematology and Transplant Center, University Hospital “San Giovanni di Dio e Ruggi d’Aragona”, Salerno, Italy
11UO di Ematologia - Catania, Catania, Italy
12ASL Salerno - Presidio Ospedaliero Tortora Pagani, Pagani, Italy
13ASSL NUORO, PRESIDIO OSPEDALIERO SAN FRANCESCO, Nuoro, Italy
14Department of Oncology and Hematology, University of Milan and ASST Papa Giovanni XXIII, Bergamo, Italy
15Department of Oncology, Division of Hematology, AOU City of Health and Science of Turin, Turin, Turin, Italy
16Azienda Sanitaria dell'Alto Adige, Bolzano, ITA
17Hematology Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
18Hematology, Azienda Ospedaliera Universitaria Senese, University of Siena, Siena, Italy
19Department of Medicine, Hematology and Clinical Immunology Unit, University of Padova, Padova, Italy
20Hematology Unit and Chair, Department of Medical and Surgical Sciences, Azienda Ospedaliera Universitaria di Modena, University of Modena and Reggio Emilia, Modena, Italy
21Department of Medicine and Surgery, Division of Hematology and Clinical Immunology, S. Maria della Misericordia Hospital, Perugia, Italy
22Ematologia, Istituto Tumori Giovanni Paolo II- Bari, Bari, Italy
23SC di Ematologia e CTMO, Ospedale Oncologico di Riferimento Regionale "A. Businco", ARNAS "G. Brotzu", Cagliari, CA, ITA
24Hematology Unit, Hematology Unit, San Bortolo Hospital, Vicenza, Italy, Vicenza, Italy
25University of Parma, Parma, ITA
26Department of Engineering for Innovation Medicine, Section of Innovation Biomedicine, Hematology Area, University of Verona, Verona, Italy
27GIMEMA Foundation, Rome, Italy
28ASO S. Croce e Carle, Cuneo, Italy
29Hematology and Bone Marrow Transplant, Unit San Raffaele Scientific Institute, Milano, Milano, Italy
30AZ. OSPEDALIERA SENESE, Siena, ITA
31Division of Hematology, Department of Translational Medicine, University of Eastern Piedmont, Novara, Italy

Introduction. Measurable residual disease (MRD) negativity represents the primary endpoint in the management of adult Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL) patients. MRD assays must be highly sensitive and specific. Droplet digital PCR (ddPCR) and next-generation sequencing (NGS) can overcome some limitations of standard methodologies. In order to evaluate the best marker for MRD monitoring, in this study we performed: i) MRD evaluation by BCR::ABL1 fusion transcript and immunoglobulin/T-cell receptor clonal gene rearrangements (IG/TR); ii) a comparison of the MRD concordance rate between the two markers; iii) a correlation with biologic features and clinical outcome.

Methods. A total of 167 samples from 111 adults enrolled in the ongoing phase III GIMEMA ALL2820 trial were collected. Samples derived from cases from both the experimental and the control arm, based respectively on ponatinib followed by blinatumomab and on a combination of imatinib and conventional chemotherapy. Established time points were day +70 (end of induction) and day +133 (after 2 cycles of blinatumomab or after 6 cycles of chemotherapy, respectively). At diagnosis, patients underwent a screening for the identification of the predominant IG/TR rearrangement by standard PCR and/or by NGS approach [LymphoTrack assay for IGH (FR1/2/3) and IGK] and the IKZF1plus signature by Multiplex Ligation-dependent Probe Amplification (MLPA). MRD monitoring was evaluated by RQ-PCR of BCR::ABL1 and, for translational research purposes, IG/TR monitoring was evaluated by ddPCR. The MRD concordance rate was evaluated comparing the results obtained between the 2 markers.

Results. Overall, 97/111 (87.4%) cases were evaluable for IG/TR MRD monitoring. At day +70, the overall concordance rate between BCR::ABL1 and IG/TR was 46.4%; 48/97 (49.5%) cases were BCR::ABL1pos; 20 were concordantly IG/TRpos (41.7%), 1 was IG/TRpositive not quantifiable and 27 were IG/TRneg; 34/97 (35%) cases were BCR::ABL1neg, 25 of which were concordantly IG/TRneg (73.5%), 5 were IG/TRpos and 4 were IG/TRpositive not quantifiable; finally, 15/97 (15.5%) cases were BCR::ABL1positive not quantifiable, 5 of which were IG/TRpos and 10 were IG/TRneg. The concordance rate was similar between IKZF1plus vs IKZF1 WT/IKZF1 loss (48.4% vs 44%), and p190 vs p210-p190/p210 (47% vs 42%) cases. At day +133, 70 patients were studied and the overall concordance rate was 41.4%: 28/70 (40%) cases were BCR::ABL1pos, 4 of which were concordantly IG/TRpos (14.3%), 2 were IG/TRpositive not quantifiable and 22 were IG/TRneg; 27/70 (38.6%) cases were BCR::ABL1neg, 25 of which were concordantly IG/TRneg (92.6%) and 2 were IG/TRpos; finally, 15/70 (21.4%) cases were BCR::ABL1positive not quantifiable and IG/TRneg. A lower concordance was observed in the IKZF1plus (24%) vs IKZF1 WT/IKZF1 loss (51%) and in the p210-p190/p210 (27.3%) compared to p190 (48%) cases. Five patients experienced a hematologic relapse. Dual monitoring was feasible in 4/5 cases (in 1 material was lacking) and, in addition to the evaluation at day +70 and +133, a retrospective backtracking was carried out at a previous time-point: 1 was concordantly BCR::ABL1pos (0.26 BCR::ABL1/ABL1 x 100) and IG/TRpos (4.0E-04), 1 was BCR::ABL1pos (7.12 BCR::ABL1/ABL1 x 100) and IG/TRneg, while the other 2 cases were both BCR::ABL1neg but IG/TRpos at 4.0E-05 and 2.0E-04, respectively, suggesting the presence at the onset of non Ph+ subclone.

Conclusions. IG/TR MRD monitoring was feasible in 87.4% of Ph+ ALL cases indicating that a fraction of patients is not suitable for this strategy. Overall, the concordance rate between BCR::ABL1 and IG/TR is limited, in line with the literature. While some groups reported a higher predictive prognostic power of IG/TR monitoring, our findings do not confirm these data, also in view of the very low rate of relapses so far observed. Nevertheless, a double-hit strategy may be informative for MRD monitoring and possibly for the distinction between typical/lymphoid Ph+ ALL vs multilineage/CML-like Ph+ ALL.

Disclosures: Borlenghi: Pfizer: Other: Travel grant; Jazz: Other: Travel grant; Amgen: Other: Travel grant. Lussana: Pfizer: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Abbvie: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Amgen: Speakers Bureau; Incyte: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Clinigen: Membership on an entity's Board of Directors or advisory committees; Bristol Myers Squibb: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau. Zappasodi: Abbvie: Honoraria; pfizer: Consultancy, Honoraria; astellas: Honoraria; Amgen: Honoraria. Bocchia: Novartis: Honoraria, Other: travel grant; Incyte: Honoraria, Other: travel grant; Abbvie: Honoraria, Other: travel grants. Bonifacio: Novartis: Membership on an entity's Board of Directors or advisory committees; Pfizer: Membership on an entity's Board of Directors or advisory committees; BMS: Membership on an entity's Board of Directors or advisory committees; Amgen: Honoraria; Incyte: Membership on an entity's Board of Directors or advisory committees. Chiaretti: Abbvie: Membership on an entity's Board of Directors or advisory committees; Incyte: Membership on an entity's Board of Directors or advisory committees; Pfizer: Membership on an entity's Board of Directors or advisory committees; Amgen: Membership on an entity's Board of Directors or advisory committees; Gilead: Membership on an entity's Board of Directors or advisory committees.

*signifies non-member of ASH